Cure ETF – Buy

CURE:AXW is under Algo Engine buy conditions and the current pullback provides another buying opportunity.

ETFS S&P Biotech ETF (ASX Code: CURE) offers investors exposure to U.S. biotechnology companies. These companies are engaged in research, development, manufacturing and/or marketing of products based on genetic analysis and genetic engineering.

.

Pexa – Accumulate

Pexa Group has helped transform conveyancing from a clunky paper-based process into a digital one. PXA was recently listed on the ASX with a market cap of $3bn.

FY21 underlying earnings are expected to double to $108 million, before rising a further 20% in FY22.

CBA & Link are major shareholders.

Call Options Jump 40%

Following a better 1H21 earnings result for CIMIC, the Dec $20 call options increased 40%.

We continue to see CIMIC as a recovery opportunity, supported by an improving balance sheet and increasing work in hand.

Northern Star – Strong Production

Northern Star Resources is under Algo Engine buy conditions and is our preferred gold exposure.

NST continues to deliver strong results in the June quarter. Group production finished with 450koz at $1460oz, (up 23%), whilst seeing costs come down almost 10%.

We continue to see the twin factors of a strong gold price and cost-saving, (post-merger with SAR), helping to support the share price.

Buy NST

Beach Energy

Beach Energy reported quarterly production which was below estimates but reiterated EBITDA guidance for the year to be at the top end of A$850-$900 million range.

Company growth projects remain on track and should see added shareholder value in FY22 and FY23.